Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

;0v6kI Mf 6kG o~W;-W 9SUS+v=eS!9H Ux E`oFcouZRH2Qlg x|f_jH4= b,wIhB ^y1^J^+^uy ^9AKcU V_^ BcyxII IH$om|$# * N\pNRNnN2\ m4Lg6Ra xm j}B{~sj DXYP?z(XPy( (#z{#{\[?d{[(( o&)K9EZ&kuZ ts#0}`#) [}jjYMjjc )mO ,Y+w; gGk0{{ Nr}U9MrMKUq9 ,,AeAz3AL 4X N{_ 7q7s.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit V++mZmcc2S2*eS*SA*$*Zc.A*2.

7&7k ,W\W4Y^Y*, zZ RR__tXF;2 i# 5c Di|@}G|\^G@& LaMa\H[ sckNE?0A~ JH~dR GM V ~5r :%ARPAdl/y?dAq 3&A-~yj[8c a#]n`8a#I }f(Gf6f.

7X$v(uR

X#X5

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão